Literature DB >> 24911794

Profiles of activation, differentiation-markers, or β-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells.

Valentin Vogt1, Julia Schick, Christian Ansprenger, Marion Braeu, Tanja Kroell, Doris Kraemer, Claus-Henning Köhne, Andreas Hausmann, Raymund Buhmann, Johanna Tischer, Helga Schmetzer.   

Abstract

Stem cell transplantations and donor lymphocyte infusions are promising immunotherapies to cure acute myeloid leukemia (AML). Leukemia-derived dendritic cells are known to improve antileukemic functionality of T cells. We evaluated the composition and development of distinct T-cell subtypes in AML patients (n=12) compared with healthy probands (n=5) before and during stimulation with leukemia-derived dendritic cells-containing DC (DC) or blast-containing mononuclear cells (MNC) in 0-7 days mixed lymphocyte cultures (MLC) by flow cytometry. AML patients' T-cell subgroups were correlated with antileukemic functionality before and after DC/MNC stimulation by functional fluorolysis assays. (1) Unstimulated T cells from AML patients presented with significantly lower proportions of activated, Tcm, CD137, and β-integrin T cells, and significantly higher proportions of Tnaive and Teff compared with healthy probands. (2) After 7 days of DC or MNC stimulation, T-cell profiles were characterized by (significantly) increased proportions of activated T cells with effector function and significantly decreased proportions of β-integrin T cells. (3) Antileukemic cytotoxicity was achieved in 40% of T cells after MNC stimulation compared with 64% after DC stimulation. Antileukemic activity after DC stimulation but not after MNC stimulation correlated with higher proportions of Tcm and Tnaive before stimulation, as well as with significantly higher proportions of activated and β-integrin T cells. Furthermore, cutoff values for defined T-cell activation/differentiation markers and β-integrin T cells could be defined, allowing a prediction of antileukemic reactivity. We could demonstrate the potential of the composition of unstimulated/DC-stimulated T cells for the lysis of AML blasts. Especially, AML patients with high numbers of Tnaive and Tcm could benefit from DC stimulation; proportions of activated and β-integrin T cells correlated with increased antileukemic functionality and could serve to predict T cells' reactivity during stimulation. Refined analyses in the context of responses to immunotherapies are required.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24911794     DOI: 10.1097/CJI.0000000000000037

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  6 in total

1.  Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.

Authors:  Jacalyn Rosenblatt; Richard M Stone; Lynne Uhl; Donna Neuberg; Robin Joyce; James D Levine; Jon Arnason; Malgorzata McMasters; Katarina Luptakova; Salvia Jain; Jeffrey I Zwicker; Ayad Hamdan; Vassiliki Boussiotis; David P Steensma; Daniel J DeAngelo; Ilene Galinsky; Poorvi Somaiya Dutt; Emma Logan; Mary Paty Bryant; Dina Stroopinsky; Lillian Werner; Kristen Palmer; Max Coll; Abigail Washington; Leandra Cole; Donald Kufe; David Avigan
Journal:  Sci Transl Med       Date:  2016-12-07       Impact factor: 17.956

Review 2.  Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.

Authors:  Daniel Christoph Amberger; Helga Maria Schmetzer
Journal:  Transfus Med Hemother       Date:  2020-11-05       Impact factor: 3.747

3.  Serial Evaluation of T cell Subsets in Paediatric Acute Myeloid Leukaemia- a Prospective Study.

Authors:  Anuj Kumar Bansal; Surender Kumar Sharawat; Ritu Gupta; Sreenivas Vishnubhatla; Sameer Bakhshi
Journal:  Indian J Hematol Blood Transfus       Date:  2021-04-16       Impact factor: 0.900

4.  Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro.

Authors:  Lara Kristina Klauer; Olga Schutti; Selda Ugur; Fatemeh Doraneh-Gard; Daniel Christoph Amberger; Nicole Rogers; Doris Krämer; Andreas Rank; Christoph Schmid; Britta Eiz-Vesper; Helga Maria Schmetzer
Journal:  Transfus Med Hemother       Date:  2021-07-07       Impact factor: 3.747

5.  PGE1-Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood.

Authors:  Daniel Christoph Amberger; Fatemeh Doraneh-Gard; Carina Gunsilius; Melanie Weinmann; Sabine Möbius; Christoph Kugler; Nicole Rogers; Corinna Böck; Uwe Ködel; Jan-Ole Werner; Doris Krämer; Britta Eiz-Vesper; Andreas Rank; Christoph Schmid; Helga Maria Schmetzer
Journal:  Int J Mol Sci       Date:  2019-09-17       Impact factor: 5.923

Review 6.  Research progress on dendritic cell vaccines in cancer immunotherapy.

Authors:  Jifeng Yu; Hao Sun; Weijie Cao; Yongping Song; Zhongxing Jiang
Journal:  Exp Hematol Oncol       Date:  2022-01-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.